专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110118258A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS 失效
标题翻译：喹诺酮衍生物作为HSP90抑制剂
公开(公告)号：US20110118258A1
公开(公告)日：2011-05-19
申请号：US12599116
申请日：2008-05-15
申请人： Stephen Martin Courtney , Mark Whittaker , Owen Clifford Mather , Christopher John Yarnold , Oliver Robin Barker , Christian Aldo Georges Napoleon Montalbetti , Thomas Hesterkamp , Mihaly Daniel Gardiner
发明人： Stephen Martin Courtney , Mark Whittaker , Owen Clifford Mather , Christopher John Yarnold , Oliver Robin Barker , Christian Aldo Georges Napoleon Montalbetti , Thomas Hesterkamp , Mihaly Daniel Gardiner
IPC分类号： A61K31/517 , C07D239/84 , C07D413/12 , C07D409/08 , C07D405/10 , C07D401/10 , C07D403/10 , C07D403/12 , A61K31/5377 , A61P35/00 , A61P29/00 , A61P31/12
CPC分类号： C07D239/84 , C07D401/04 , C07D403/10 , C07D405/04 , C07D409/04
摘要： Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.
摘要翻译：通式（I）的化合物; 或其立体异构体，互变异构体，药学上可接受的盐或前药，其中R 1，R 2，R 3，R 4，R 5，R 6，R 8和R 9如本文所定义，可用于治疗疾病和病症，不适当的Hsp90活动如癌症，病毒感染和炎性疾病或病症。

2. 发明授权

US08592430B2 Quinazolin-oxime derivatives as Hsp90 inhibitors 失效
标题翻译：喹唑啉肟衍生物作为Hsp90抑制剂
公开(公告)号：US08592430B2
公开(公告)日：2013-11-26
申请号：US12599116
申请日：2008-05-15
申请人： Stephen Martin Courtney , Mark Whittaker , Owen Clifford Mather , Christopher John Yarnold , Oliver Robin Barker , Christian Aldo Georges Napoleon Montalbetti , Thomas Hesterkamp , Mihaly Daniel Gardiner
发明人： Stephen Martin Courtney , Mark Whittaker , Owen Clifford Mather , Christopher John Yarnold , Oliver Robin Barker , Christian Aldo Georges Napoleon Montalbetti , Thomas Hesterkamp , Mihaly Daniel Gardiner
IPC分类号： A61K31/517 , A61K31/519 , C07D239/84
CPC分类号： C07D239/84 , C07D401/04 , C07D403/10 , C07D405/04 , C07D409/04
摘要： Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.
摘要翻译：通式（I）的化合物; 或其立体异构体，互变异构体，药学上可接受的盐或前药，其中R 1，R 2，R 3，R 4，R 5，R 6，R 8和R 9如本文所定义，可用于治疗疾病和病症，不适当的Hsp90活动如癌症，病毒感染和炎性疾病或病症。

3. 发明授权

US08563536B2 Compounds having CRTH2 antagonist activity 有权
标题翻译：具有CRTH2拮抗活性的化合物
公开(公告)号：US08563536B2
公开(公告)日：2013-10-22
申请号：US13017860
申请日：2011-01-31
申请人： Richard Edward Armer , Eric Roy Pettipher , Mark Whittaker , Graham Michael Wynne , Julia Vile , Frank Schroer
发明人： Richard Edward Armer , Eric Roy Pettipher , Mark Whittaker , Graham Michael Wynne , Julia Vile , Frank Schroer
IPC分类号： A61K31/70 , A61K31/56 , A61K31/50 , A61K31/47 , A61K31/44
CPC分类号： A61K31/4439 , A61K31/47 , A61K45/06 , C07D401/06
摘要： Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
摘要翻译：通式（II）的化合物，其中W是氯或氟; R 1是任选被一个或多个选自卤素，-CN，-C 1 -C 6烷基，-SOR 3，-SO 2 R 3，-SO 2 N（R 2）2，-N（R 2）2，-NR 2 C（O）R 3 ，-CO 2 R 2，-CONR 2 R 3，-NO 2，-OR 2，-SR 2，-O（CH 2）pOR 2或-O（CH 2）p O（CH 2）q OR 2，其中每个R 2独立地是氢，-C 1 -C 6烷基， C8环烷基，芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基，-C 3 -C 8环烷基，芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基，（CH2）mOC（= O）C1-C6烷基，（（CH2）mO）nCH2CH2X，（CH2）mN（R5）2或CH （（CH 2）m O（C = O）R 6）2; m为1或2; n为1-4; X为OR 5或N（R 5）2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐，水合物，溶剂合物，复合物或前药可用于口服给药的组合物中，用于治疗过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎。

4. 发明授权

US08536158B2 Compounds having CRTH2 antagonist activity 有权
标题翻译：具有CRTH2拮抗活性的化合物
公开(公告)号：US08536158B2
公开(公告)日：2013-09-17
申请号：US13014314
申请日：2011-01-26
申请人： Richard Edward Armer , Eric Roy Pettipher , Mark Whittaker , Graham Michael Wynne , Julia Vile , Frank Schroer
发明人： Richard Edward Armer , Eric Roy Pettipher , Mark Whittaker , Graham Michael Wynne , Julia Vile , Frank Schroer
IPC分类号： A61K31/70 , A61K31/56 , A61K31/50 , A61K31/47 , A61K31/44
CPC分类号： A61K31/4439 , A61K31/47 , A61K45/06 , C07D401/06
摘要： Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
摘要翻译：通式（I）的化合物，其中W是氯或氟; R 1是任选被一个或多个选自卤素，-CN，-C 1 -C 6烷基，-SOR 3，-SO 2 R 3，-SO 2 N（R 2）2，-N（R 2）2，-NR 2 C（O）R 3 ，-CO 2 R 2，-CONR 2 R 3，-NO 2，-OR 2，-SR 2，-O（CH 2）pOR 2或-O（CH 2）p O（CH 2）q OR 2，其中每个R 2独立地是氢，-C 1 -C 6烷基， C8环烷基，芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基，-C 3 -C 8环烷基，芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基，（CH2）mOC（= O）C1-C6烷基，（（CH2）mO）nCH2CH2X，（CH2）mN（R5）2或CH （（CH 2）m O（C = O）R 6）2; m为1或2; n为1-4; X为OR 5或N（R 5）2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐，水合物，溶剂合物，复合物或前药可用于口服给药的组合物中，用于治疗过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎。

5. 发明申请

US20110269742A1 Serotonin 5-HT2B Receptor Inhibitors 有权
标题翻译： 5-羟色胺5-HT2B受体抑制剂
公开(公告)号：US20110269742A1
公开(公告)日：2011-11-03
申请号：US13139363
申请日：2009-12-14
申请人： Derek Cogan , Neil Moss , Christopher Ronald Sarko , Samantha Jayne Bamford , Pui Leng Loke , Spencer Charles R. Napier , Heather Tye , Mark Whittaker
发明人： Derek Cogan , Neil Moss , Christopher Ronald Sarko , Samantha Jayne Bamford , Pui Leng Loke , Spencer Charles R. Napier , Heather Tye , Mark Whittaker
IPC分类号： A61K31/454 , C07D401/14 , C07D403/04 , A61K31/4545 , A61K31/506 , A61K31/4439 , A61K31/4178 , A61P9/00 , A61P9/12 , A61P25/06 , A61P15/10 , A61P29/00 , A61P1/00 , A61P25/24 , A61P25/22 , A61P25/28 , A61P25/16 , A61P11/06 , A61P11/00 , A61P13/08 , A61P25/00 , C07D401/04
CPC分类号： C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.
摘要翻译：公开了式I的5-羟色胺5-HT 2B受体抑制剂。还公开了制备方法和使用这些化合物的方法。

6. 发明申请

US20100063103A1 Compounds Having CRTH2 Antagonist Activity 有权
标题翻译：具有CRTH2拮抗作用的化合物
公开(公告)号：US20100063103A1
公开(公告)日：2010-03-11
申请号：US12625497
申请日：2009-11-24
申请人： Richard Edward ARMER , Eric Roy Pettipher , Mark Whittaker , Graham Michael Wynne , Julia Vile , Frank Schroer
发明人： Richard Edward ARMER , Eric Roy Pettipher , Mark Whittaker , Graham Michael Wynne , Julia Vile , Frank Schroer
IPC分类号： A61K31/4439 , C07D401/06 , A61P37/08
CPC分类号： A61K31/4439 , A61K31/47 , A61K45/06 , C07D401/06
摘要： Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
摘要翻译：通式（I）的化合物，其中W是氯或氟; R 1是任选被一个或多个选自卤素，-CN，-C 1 -C 6烷基，-SOR 3，-SO 2 R 3，-SO 2 N（R 2）2，-N（R 2）2，-NR 2 C（O）R 3 ，-CO 2 R 2，-CONR 2 R 3，-NO 2，-OR 2，-SR 2，-O（CH 2）pOR 2或-O（CH 2）p O（CH 2）q OR 2，其中每个R 2独立地是氢，-C 1 -C 6烷基， C8环烷基，芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基，-C 3 -C 8环烷基，芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基，（CH2）mOC（= O）C1-C6烷基，（（CH2）mO）nCH2CH2X，（CH2）mN（R5）2或CH （（CH 2）m O（C = O）R 6）2; m为1或2; n为1-4; X为OR 5或N（R 5）2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐，水合物，溶剂合物，复合物或前药可用于口服给药的组合物中，用于治疗过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎。

7. 发明申请

US20070015799A1 Glyoxalase inhibitors 审中-公开
标题翻译：乙二醛酶抑制剂
公开(公告)号：US20070015799A1
公开(公告)日：2007-01-18
申请号：US10556901
申请日：2004-05-14
申请人： Mark Ashton , Alan Davidson , Russell Thomas , Mark Whittaker
发明人： Mark Ashton , Alan Davidson , Russell Thomas , Mark Whittaker
IPC分类号： A61K31/4436 , A61K31/44 , A61K31/381
CPC分类号： C07D405/04 , A61K31/10 , A61K31/381 , A61K31/44 , A61K31/4436 , C07C323/62 , C07D213/85 , C07D217/26 , C07D409/04 , C07D409/14
摘要： This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase 1. Wherein X is N or CH. R2 is H, CF3; or optionally substituted C5-6 aryl, C3-7 cycloalkyl, C5-7 heterocyclyl. R3 is H; or optionally substituted C5-6 aryl, C3-7 cycloalkyl, C5-7 heterocyclyl. Alternatively R2 and R3 together form an optionally substituted C3-4alkylene group wherein L3 and L4 are single bonds thus forming a C5-6 ring fused with the aromatic ring to which L3 and L4 are attached. L3 and L4 are independently selected from a single bond, optionally substituted C1-4 alkylene, -L9YN(OH)C(═O)L10- and -L9C(═O)N(OH)YL10-, wherein L9 and L10 are independently selected from optionally substituted C1-4 alkylene, C5-6 arylene, C1-4 alkylene-C5-6arylene and a single bond, wherein Y is NH or a single bond.
摘要翻译：本发明涉及作为乙二醛酶I抑制剂的式（I）化合物，包含这些化合物的药物盐或组合物，以及这些组合物和化合物用于治疗通过抑制乙二醛酶1减轻的各种病症的用途。其中X是N或CH 。 R 2是H，CF 3 N; 或任选取代的C 5-6芳基，C 3-7环烷基，C 5-7杂环基。 R 3是H; 或任选取代的C 5-6芳基，C 3-7环烷基，C 5-7杂环基。或者R 2和R 3一起形成任选取代的C 3-4亚烷基，其中L 3和L 3 因此形成与L 3和L 4的芳环稠合的C 5〜6环， SUP>连接。 L 3和L 4独立地选自单键，任选取代的C 1-4亚烷基，-L 9， SUP-YN（OH）C（-O）L 10 - 和-L 9 C（ - ）N（OH）Y L 10 - ，其中L 9和L 10独立地选自任选取代的C 1-4 - 亚烷基，C 5-6 - 亚芳基，C 1-4亚烷基-C 5-6亚芳基和单键，其中Y是NH或单键。

8. 发明申请

US20060276409A1 Antibacterial agents 失效
标题翻译：抗菌剂
公开(公告)号：US20060276409A1
公开(公告)日：2006-12-07
申请号：US11497277
申请日：2006-08-02
申请人： Michael Hunter , Raymond Beckett , John Clements , Mark Whittaker , Stephen Davies , Lisa Pratt , Zoe Spavold , Steven Launchbury
发明人： Michael Hunter , Raymond Beckett , John Clements , Mark Whittaker , Stephen Davies , Lisa Pratt , Zoe Spavold , Steven Launchbury
IPC分类号： A61K38/05 , A61K38/04 , A61K31/445 , A61K31/34 , A61K31/198
CPC分类号： C07C259/06 , A61K31/00 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/198 , A61K31/40 , A61K31/401 , A61K31/4402 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/472 , A61K31/495 , A61K31/5375 , C07C239/14 , C07C323/60 , C07C2601/08 , C07C2601/14 , C07D213/75 , C07D217/26 , C07D263/26 , C07D295/185 , C07K5/0202
摘要： Compounds of formula (I) are antibacterials: wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n-(ALK)m- wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and m and n are independently 0 or 1; and A represents a group as defined in the specification.
摘要翻译：式（I）的化合物是抗细菌剂：其中：R 1表示氢或C 1 -C 6烷基或C 1 被一个或多个卤素原子取代的C 6 -C 6烷基; R 2表示基团R 10 - （X）n - （ALK）m - 其中R _{10 表示氢或C 1 -C 6烷基，C 2 -C 6亚烷基，C 2 -C 6 烯基，C 2 -C 6炔基，环烷基，芳基或杂环基，其中任何一个可以是未被取代的或被（C 1〜（C 1 -C 6）烷基，（C 1 -C 6 -C 6）烷氧基，羟基，巯基，（C 1 -C 6）烷基，烷基硫基，氨基，卤代（包括氟，氯，溴和碘），三氟甲基，氰基，硝基，-COOH，-CONH 2 - ， - COOR 其中，-NHCOR，A，A，A，A，O，或其中R A和R B各自独立地选自：其中R A，R B，R B， SUP>独立地为（C 1 -C 6 -C 6）烷基，ALK表示直链或支链二价C 1 -C 3 > 6个亚烷基，C 2 -C 6亚烯基或C 2 -C 6亚炔基（C 1 -C 6亚烷基）激进并且可以被一个或多个不相邻的-NH-，-O-或-S-键中断，X表示-NH-，-O-或-S-，m和n独立地为0或1; 并且A表示说明书中定义的组。}

9. 发明授权

US06787522B2 Antibacterial agents 失效
标题翻译：抗菌剂
公开(公告)号：US06787522B2
公开(公告)日：2004-09-07
申请号：US10134754
申请日：2002-04-30
申请人： Michael George Hunter , Raymond Paul Beckett , John Martin Clements , Mark Whittaker , Stephen John Davies , Lisa Marie Pratt , Zoe Marie Spavold , Steven Launchbury
发明人： Michael George Hunter , Raymond Paul Beckett , John Martin Clements , Mark Whittaker , Stephen John Davies , Lisa Marie Pratt , Zoe Marie Spavold , Steven Launchbury
IPC分类号： A61K3116
CPC分类号： C07C259/06 , A61K31/00 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/198 , A61K31/40 , A61K31/401 , A61K31/4402 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/472 , A61K31/495 , A61K31/5375 , C07C239/14 , C07C323/60 , C07C2601/08 , C07C2601/14 , C07D213/75 , C07D217/26 , C07D263/26 , C07D295/185 , C07K5/0202
摘要： Compounds of formula (I) are antibacterials: wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n—(ALK)m— wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and m and n are independently 0 or 1; and A represents a group as defined in the specification.
摘要翻译：式（I）化合物是抗菌剂：其中：R1代表氢，或C1-C6烷基或被一个或多个卤原子取代的C1-C6烷基; R 2表示R 10 - （X）n-（ALK）m - ，其中R 10表示氢，或C 1 -C 6烷基，C 2 -C 6烯基，C 2 -C 6炔基，环烷基，芳基或杂环基，其中任何一个可以羟基，巯基，（C 1 -C 6）烷硫基，氨基，卤素（包括氟，氯，溴和碘），三氟甲基，氰基，硝基，（C 1 -C 6）烷氧基， -COOH，-CONH 2，-COOR A，-NHCOR A，-CONHR A，-NHR A，-NR A R B或-CONR R B，其中R A和R B独立地为（C 1 -C 6）烷基，并且ALK表示直链或支链二价C 1 -C 6亚烷基，C 2 -C 6亚烯基或C 2 -C 6亚炔基，并且可被中断通过一个或多个不相邻的-NH-，-O-或-S-键，X表示-NH-，-O-或-S-，m和n独立地为0或1; 并且A表示说明书中定义的组。

10. 发明授权

US06503897B1 Antibacterial agents 失效
标题翻译：抗菌剂
公开(公告)号：US06503897B1
公开(公告)日：2003-01-07
申请号：US09914049
申请日：2001-08-22
申请人： Raymond Paul Beckett , Mark Whittaker , Zoe Marie Spavold
发明人： Raymond Paul Beckett , Mark Whittaker , Zoe Marie Spavold
IPC分类号： C07D28106
CPC分类号： C07D513/04 , C07D211/76 , C07D223/12 , C07D225/02 , C07D243/08 , C07D245/02 , C07D281/06 , C07D327/02
摘要： Compounds of formula (I) are antibacterial agents wherein: R3 and R4, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atoms, which may be benz-fused or fused to a second optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atoms; and R1 and R2 are as defined in the specification.
摘要翻译：式（I）化合物是抗菌剂，其中：R3和R4与它们分别连接的碳原子一起形成任选取代的5至16个原子的饱和碳环或杂环，其可以是苯并稠合的或与5至16个原子的第二任选取代的饱和碳环或杂环稠合; R1和R2如说明书中所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式